2015
DOI: 10.31768/2312-8852.2015.37(4):292-294
|View full text |Cite
|
Sign up to set email alerts
|

IMPACT OF KRAS VARIANT rs61764370 ON BREAST CANCER MORBIDITY

Abstract: Low-penetrance gene variants and their combinations are topical study objects in breast cancer pathogenesis. Single nucleotide polymorphism rs61764370, localized in 3 UTR of KRAS gene, plays an important role in the development and progression of several cancers. The aim of our study was to determine the KRAS variant impact on breast cancer morbidity. Patients and Methods: 2214 patients diagnosed with breast cancer and 861 healthy controls were screened for KRAS variant by RFLP method. Available clinical data … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2018
2018
2020
2020

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 7 publications
0
2
0
Order By: Relevance
“…Notably, GWAS studies of a SNP linked to rs61764370 did not find significant association with risk of breast or ovarian cancer [51]. However, well-constructed case control studies that stratify patients by age [52], hormone levels [48], or Her2 status [49,50] have found significant associations between the KRAS -variant and BC risk and biology. Together, these data highlight the importance of proper contextualization of miR-SNPs like the KRAS -variant when determining patient risk, and suggest that large cohorts with less robust clinical annotation may not be the best place to define the clinical biology and utility of miR-SNPs, which are clearly context dependent, being influenced by environmental conditions, such as estrogen.…”
Section: The Kras-variant and Breast Cancer Riskmentioning
confidence: 99%
“…Notably, GWAS studies of a SNP linked to rs61764370 did not find significant association with risk of breast or ovarian cancer [51]. However, well-constructed case control studies that stratify patients by age [52], hormone levels [48], or Her2 status [49,50] have found significant associations between the KRAS -variant and BC risk and biology. Together, these data highlight the importance of proper contextualization of miR-SNPs like the KRAS -variant when determining patient risk, and suggest that large cohorts with less robust clinical annotation may not be the best place to define the clinical biology and utility of miR-SNPs, which are clearly context dependent, being influenced by environmental conditions, such as estrogen.…”
Section: The Kras-variant and Breast Cancer Riskmentioning
confidence: 99%
“…Contrary, Hollestelle et al, stated that KRAS variant (rs61764370 T>G) frequencies might be increased among BRCA1 carriers but not BRCA2 or non BRCA1/BRCA2 families among controls (15). On the other hand, Paranjape et al, (16) and Ustinova et al, (17) found that, the KRAS variant was significantly associated with breast cancer at menopausal age. Another study by Pilarski,et al,(18), found that KRAS variant is considered as a genetic marker for hereditary breast ovarian cancer families.…”
Section: Resultsmentioning
confidence: 94%